Boston Scientific’s Obsidio Embolic Posts Clean 30-Day Results in Company-Sponsored Registry

Photo: Marcel Scholte / Unsplash

The OCCLUDE registry, now published in JVIR, reports complete target-vessel occlusion in 125 patients, though it had no comparison group and only a month of follow-up.

Background

Embolization, deliberately blocking a blood vessel from the inside, is a core tool of interventional radiology, used to stop bleeding and to starve tumors of their blood supply. Physicians have long had a menu of agents for the job, including metal coils, particles and gelatin sponge.

Obsidio Conformable Embolic, made by Boston Scientific, is a premixed gel of pre-hydrated gelatin and layered silicate, with tantalum powder added so it shows up on fluoroscopy [1]. It is delivered through a microcatheter and, according to the FDA clearance summary, conforms to the shape of the vessel "without relying on precipitation or polymerization" [1]. In short, it is a putty that knows where it is supposed to stop.

Obsidio is regulated through the FDA's 510(k) pathway; an earlier version was cleared on July 1, 2022 (K213385) [1]. A later clearance, issued October 3, 2024 (K242507), lists its indications as embolization of hypervascular tumors and of blood vessels to control bleeding or hemorrhage in the peripheral vasculature [1].

What Was Found

The OCCLUDE registry (NCT06170619) enrolled 125 patients consecutively at 19 U.S. hospitals, according to Boston Scientific [2,3]. Results were published in the Journal of Vascular and Interventional Radiology by Ketan Y. Shah, MD, and colleagues, and announced by the company on November 17 [3].

Patients ranged in age from 18 to 92, with a mean age of 59.1 years; 63.2% were men [2]. The most common health conditions were hypertension (54.4%), active cancer (36.0%) and diabetes (23.2%) [2]. The registry covered a wide range of anatomy: among 161 target lesions, the kidney's blood vessels were most common (25.5%), followed by musculoskeletal sites (19.3%), the inferior epigastric artery (9.9%), the upper gastrointestinal tract (9.3%), the liver (9.3%), the spleen (6.2%) and the lower gastrointestinal tract (2.5%) [2].

The company reports the following results [2,3]:

  • Occlusion: The primary effectiveness endpoint, target-vessel occlusion immediately after the procedure, was achieved in 100% of cases across 19 target-vessel types.

  • Rebleeding: No target-vessel rebleeding was reported through 30 days, and no target-vessel reintervention was needed.

  • Safety: Freedom from major adverse events through 30 days, the primary safety endpoint, was 97.4%, as reported by Endovascular Today from the company's announcement [3].

  • Combination use: Obsidio was used together with other embolics, including coils, particles or beads and gelatin sponge, in 38 vessels, or 23.6% [2,3].

That last figure deserves attention. Nearly a quarter of the time, operators reached for a second agent, which makes it harder to credit occlusion to Obsidio alone in those cases.

Study Design and Limitations

OCCLUDE was sponsored by Boston Scientific [3,4]. It is a prospective, post-approval, open-label, single-arm registry: every patient received Obsidio, and there was no comparison group treated with coils, particles or another agent [2,4]. That design can show how a device performs in routine practice, but it cannot show that the device is better than, or even equivalent to, the alternatives.

Follow-up for the reported endpoints ended at 30 days [2]. That is enough to capture early rebleeding and procedural complications, but not later recanalization, in which a blocked vessel reopens, or long-term outcomes for patients treated for tumors. Because patients with very different conditions were pooled, the 125-patient sample is spread thin across individual indications; results for any single use, such as splenic or gastrointestinal bleeding, rest on small numbers. Occlusion was also assessed by treating teams in an open-label setting.

VBN was unable to access the full JVIR paper or its abstract, so the authors' disclosures of financial relationships with Boston Scientific, and their own description of the study's limitations, could not be reviewed for this article. Results above are drawn from the company's registry summary and Endovascular Today's report of its announcement [2,3].

What Comes Next

For interventional radiologists, OCCLUDE offers multicenter, real-world data on a relatively new embolic across a broad mix of cases, with no rebleeding signal in the first month. The more useful next steps would be longer follow-up, indication-specific analyses and, ideally, comparative studies against established agents. Until then, the data show what Obsidio did in a sponsor-run registry, not how it stacks up against the coils already on the shelf.

This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.

References

  1. U.S. Food and Drug Administration. 510(k) premarket notification K242507: Obsidio Conformable Embolic (Boston Scientific Corporation). Decision date October 3, 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242507.pdf

  2. Boston Scientific. Obsidio OCCLUDE registry. Boston Scientific (physician data page). Accessed November 19, 2026. https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology/obsidio-conformable-embolic/data/obsidio-occlude-registry.html

  3. Endovascular Today. OCCLUDE registry data published for Boston Scientific's Obsidio conformable embolic. Endovascular Today. November 17, 2026. https://evtoday.com/news/occlude-registry-data-published-for-boston-scientifics-obsidio-conformable-embolic

  4. ClinicalTrials.gov record NCT06170619, Obsidio Conformable Embolic Registry, as mirrored by Veeva Clinical Trials. Accessed November 19, 2026. https://ctv.veeva.com/study/a-prospective-post-approval-open-label-multi-center-united-states-us-registry-to-evaluate-the-e

Phillip Leblanc

What I cover

I write wellness and medical culture pieces for The Culture Desk RX: strangers sweating it out in a street sauna, doctors with unusual side hustles, and the general human comedy of trying to stay healthy. A good fraud story and a good sauna story have more in common than you’d think. Somebody’s always sweating.

I’ve seen everything from kickbacks dressed up as “consulting fees” to charities that are generous mostly to their own founders. If a dollar goes missing between the patient and the provider, I find it.

I focus on interventional radiology and the quiet evolution of robotic systems that are breaking medical ceilings, healing patients with catheters instead of scalpels. I believe in the good guys, so I write about altruistic causes: the nurses, doctors and nonprofits doing honest work with no PR team.

My Background

Growing up in East Durham, North Carolina, you learn two things: how to throw a jab and when to keep your mouth closed. My editor says it explains my interviewing style.

Journalistic Ethics

Vital Biomedical News is reader-funded and beholden to no one. We take no money from pharmaceutical or medical device companies, and neither do I. I don’t accept gifts, junkets or favors, and I don’t bankroll political causes. My only allegiance is to the paper trail.

I deal in documents, not anecdotes. Every claim is corroborated against primary sources: court filings, federal records, clinical data and the people who were actually in the room. Sources get candor, confidential sources get anonymity, and powerful institutions get scrutiny, whether they welcome it or not.

I’m unfailingly courteous to everyone I interview, including the people I’m investigating. Civility is not clemency.

Previous
Previous

Shanghai Dismisses Two Researchers After Child’s Death in Experimental Gene-Editing Treatment

Next
Next

Former NIH Aging Institute Neuroscience Chief Eliezer Masliah Passes 30 Retractions